CooperCompanies stock, medical devices

CooperCompanies stock holds at USD 55.38 after guidance reset

Published on 09/28/2026 at 13:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CooperCompanies stock posted USD 1.066 billion in fiscal Q3 revenue on September 9, 2026, with adjusted EPS at USD 1.15. Fiscal 2026 guidance points to USD 4.51-4.55 EPS.

Reinraum-Produktionsanlage für medizinische Geräte mit Technikern an Kontaktlinsen-Fertigungslinien
CooperCompanies Reinraum-Produktion US21664P1039 zeigt automatisierte Kontaktlinsen-Fertigungslinien mit optischer Qualitätsprüfung im sterilen Reinraumbereich, Illustration mit AI erstellt.

CooperCompanies stock held at a closing price of USD 55.38 on Nasdaq on September 25, 2026, after the medical device maker reduced its fiscal 2026 outlook earlier in September. The latest quarterly report showed revenue of USD 1.066 billion for the fiscal third quarter ended July 31, 2026, up 1.00 percent year over year, according to CooperCompanies on September 9, 2026.

Guidance sets the central test

CooperCompanies reported non-GAAP diluted EPS of USD 1.15 in fiscal Q3 2026, up 4.00 percent from the prior-year quarter. GAAP diluted EPS reached USD 2.24, but a USD 307.2 million discrete tax benefit was the primary reason for the sharp difference between GAAP and adjusted earnings.

The company guided to fiscal 2026 revenue of USD 4.229-4.252 billion and non-GAAP diluted EPS of USD 4.51-4.55. For fiscal Q4, management expects revenue of USD 1.057-1.080 billion and adjusted EPS of USD 1.05-1.09, while CooperVision organic growth is guided at negative 2.00 percent to 0.00 percent.

Buyback offsets strategic disappointment

The board expanded the share repurchase authorization from USD 2 billion to USD 3 billion after completing its strategic review. In the release dated September 9, 2026, GlobeNewswire reported that the board chose to retain CooperSurgical after deciding that potential offers did not adequately serve shareholders.

Cash generation was a stronger counterpoint. Free cash flow rose 66.00 percent year over year to USD 273.0 million in the quarter, and CooperCompanies repurchased USD 339.1 million of common stock. The operating picture is therefore divided between improved cash flow and pressure on contact-lens distribution, where U.S. channel inventory reduction weighed on CooperVision.

Analyst targets reset lower

Needham lowered its price target from USD 86.00 to USD 73.00 on September 10, 2026, while maintaining a Buy rating, according to Investing.com. The new target stood 31.78 percent above the September 25 closing price. MarketBeat reported an analyst consensus of Hold and an average 12-month target of USD 71.47 on September 26, 2026.

Stock stays near its yearly floor

CooperCompanies stock had a 52-week range of USD 51.01 to USD 89.83 and a market capitalization of USD 10.8 billion as of September 25, 2026. The next earnings report is scheduled for December 3, 2026, according to Investing.com.

CooperCompanies market data

  • Company: The Cooper Companies, Inc.
  • Ticker: COO
  • Trading venue: Nasdaq
  • Price: USD 55.38, closing price September 25, 2026
  • Market capitalization: USD 10.8 billion as of September 25, 2026
  • 52-week range: USD 51.01-89.83 as of September 25, 2026
  • Volume: 4,454,020 shares on September 25, 2026
  • Sector / Industry: Healthcare / Medical instruments and supplies
  • Next earnings date: December 3, 2026

Disclaimer...

en | boerse | 70192539 |